Marshall Financial Group LLC Boosts Stock Position in Novo Nordisk A/S (NYSE:NVO)

Marshall Financial Group LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 5.3% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,953 shares of the company’s stock after buying an additional 702 shares during the quarter. Marshall Financial Group LLC’s holdings in Novo Nordisk A/S were worth $1,792,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of NVO. Westside Investment Management Inc. boosted its stake in Novo Nordisk A/S by 83.3% in the third quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock valued at $130,000 after acquiring an additional 649 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Novo Nordisk A/S by 38.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock worth $9,781,000 after purchasing an additional 26,067 shares in the last quarter. Advisor Resource Council purchased a new position in Novo Nordisk A/S during the 4th quarter worth $997,000. Procyon Advisors LLC increased its position in Novo Nordisk A/S by 47.7% during the 4th quarter. Procyon Advisors LLC now owns 55,026 shares of the company’s stock valued at $5,692,000 after buying an additional 17,783 shares in the last quarter. Finally, McKinley Carter Wealth Services Inc. raised its stake in Novo Nordisk A/S by 37.0% in the fourth quarter. McKinley Carter Wealth Services Inc. now owns 60,356 shares of the company’s stock valued at $6,244,000 after buying an additional 16,293 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Argus boosted their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. The Goldman Sachs Group initiated coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $163.00 price target on shares of Novo Nordisk A/S in a report on Tuesday, June 25th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus price target of $145.67.

Novo Nordisk A/S Stock Performance

NVO traded down $4.11 during trading on Thursday, reaching $138.87. 7,455,753 shares of the company’s stock were exchanged, compared to its average volume of 3,491,449. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $148.15. The company’s fifty day simple moving average is $135.95 and its 200-day simple moving average is $124.47. The stock has a market capitalization of $623.18 billion, a P/E ratio of 47.89, a price-to-earnings-growth ratio of 1.41 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.06. The firm had revenue of $9.52 billion during the quarter, compared to analysts’ expectations of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. As a group, research analysts predict that Novo Nordisk A/S will post 3.44 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.